4 completed, 3 recruiting. 7 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 4, Recruiting 3 |
| Phase 2 | 1 | Recruiting 1 |
Follow PMV Pharmaceuticals, Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. metformin hydrochloride 500 mg tablet, rosuvastatin 10 mg tablet, repaglinide 0.5 mg tablet - TP53 Y220C Mutation, Advanced Solid Tumors | Phase 1 | Recruiting | PMV Pharmaceuticals, Inc | 14 | 2026-02-04 | 2026-08-12 |
| A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome) Azacitidine, Rezatapopt - Myelodysplastic Syndrome, Acute Myeloid Leukemia | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 24 | 2025-01-30 | 2026-10-09 |
| A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of PC14586 in Healthy Participants PC14586, Itraconazole - Healthy Volunteers | Phase 1 | Completed | PMV Pharmaceuticals, Inc | 12 | 2024-03-28 | 2024-11-13 |
| A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy Participants PC14586, Rabeprazole, Famotidine - Healthy Volunteers | Phase 1 | Completed | PMV Pharmaceuticals, Inc | 28 | 2023-09-19 | 2024-11-13 |
| AME Study of [14C]-PC14586 in Healthy Male Participants [14C]-PC14586 - Healthy Male Volunteers | Phase 1 | Completed | PMV Pharmaceuticals, Inc | 8 | 2022-09-06 | 2022-12-20 |
| Effect of Food on PC14586 in Healthy Volunteers and the PK of PC14586 in Healthy Japanese Volunteers PC14586 - Healthy Volunteers | Phase 1 | Completed | PMV Pharmaceuticals, Inc | 34 | 2021-12-20 | 2024-11-13 |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) rezatapopt, pembrolizumab - Advanced Solid Tumor, Advanced Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | PMV Pharmaceuticals, Inc | 300 | 2020-10-29 | 2026-10-02 |
Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Gallbladder Neoplasms (1) · Head and Neck Neoplasms (1) · Leukemia, Myeloid, Acute (1) · Lung Neoplasms (1) · Myelodysplastic Syndromes (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Prostatic Neoplasms (1) · Small Cell Lung Carcinoma (1) · Triple Negative Breast Neoplasms (1)
Azacitidine (1) · Famotidine (1) · Itraconazole (1) · Metformin (1) · Rabeprazole (1) · Rosuvastatin Calcium (1) · Tablets (1) · pembrolizumab (1) · repaglinide (1)
United States (7) · Australia (1) · France (1) · Germany (1) · Italy (1) · Singapore (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Courtney DiNardo, MD (1) · Deepak Bhamidipati, MD (1) · Marc Fellous, MD (1)